布地奈德缓释胶囊可以治愈IGA肾病吗?

Budesonide extended-release capsules can cure IGA nephropathy. As early as 2001, budesonide extended-release capsules were approved by the US FDA for mild to moderately active Crohn's disease (an intestinal autoimmune disease) involving the ileum and ascending colon. In fact, in addition to being widely used to treat Crohn's disease, it has also completed phase II clinical studies for IgA nephropathy and has obtained orphan drug status granted by the European Union and the US FDA.

About IGA Nephropathy

IgA nephropathy (IgAN) is currently the most common primary glomerular disease in my country, and its main clinical manifestations include episodic hematuria, proteinuria, hypertension, and impaired renal function. IgAN is the primary cause of end-stage kidney disease (ESKD) in my country, seriously affecting patients' quality of life and life expectancy. In recent years, glucocorticoid treatment has seriously affected patients' quality of life and life expectancy.

Experimental study of budesonide sustained-release capsules in the treatment of IGA nephropathy

Professor Bengt C Fellström from Uppsala University in Sweden conducted a clinical study on targeted therapy for IgAN [1]. The results of the study have been published in The Lancet. This is a randomized, double-blind controlled trial, currently in phase 2b. Its purpose is to evaluate the efficacy and safety of budesonide sustained-release capsules in the treatment of IgAN. In the trial, 150 patients with primary IgAN were randomly divided into 3 groups, who were given budesonide sustained-release capsules 8 mg/d, 16 mg/d, and placebo respectively, with basic RAS blocking treatment. After 9 months of treatment, the urinary protein and creatinine of patients with budesonide sustained-release capsules (16 mg/d, 8 mg/d) decreased by 24.4% (27.3%, 21.5%) compared with the baseline. , while the urinary protein and creatinine in the placebo group only decreased by 0.74% compared with the baseline, and there was no significant difference in the incidence of adverse events among the three groups. Researchers believe that budesonide sustained-release capsules combined with RASB can effectively reduce urinary protein in patients with IgAN.

References

[1] Fellstr m BC, Barratt J, Cook H, et al. Targeted-release budes-onide versus placebo in patients with IgA nephropathy (NEFI-GAN): a double-blind, randomized, placebo-controlled phase2b trial. Lancet, 2017, 389(10084): 2117.

Recommended related articles: